Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Randomized, Placebo-controlled Parallel Group Clinical Trial of Nicotinamide Riboside to Evaluate NAD+ Levels in Individuals With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)
Sponsor: Massachusetts General Hospital
Listed as NCT04809974, this PHASE4 trial focuses on Cognitive Symptom and Covid19 and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 10 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2025 — Aug 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Jul 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Sep 2022 — Apr 2024 [monthly]
Recruiting PHASE4
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .